Theranostic Lipid Nanoparticles for Renal Cell Carcinoma
Advanced Materials · 2025-08 · 37 (31)
DOI: 10.1002/adma.202306246 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Materials, online erschienen am 03.12.2023. Verfasst von Xiongmin Mao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Cancer Precision Diagnosis and Treatment and Translational Medicine Hubei Engineering Research Center, Zhongnan Hospital of Wu…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Theranostic Nanomedicine, Nanoparticles, Kidney Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 249 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Renal cell carcinoma (RCC) is a common urological malignancy and represents a leading threat to healthcare. Recent years have seen a series of progresses in the early diagnosis and management of RCC. Theranostic lipid nanoparticles (LNPs) are increasingly becoming one of the focuses in this field, because of their suitability for tumor targeting and multimodal therapy. LNPs can be precisely fabricated with desirable chemical compositions and biomedical properties, which closely match the physiological characteristics and clinical needs of RCC. Herein, a comprehensive review of theranostic LNPs is presented, emphasizing the generic tool nature of LNPs in developing advanced micro‐nano biomaterials. It begins with a brief overview of the compositions and formation mechanism of LNPs, followed with an introduction to kidney‐targeting approaches, such as passive, active, and stimulus responsive targeting. With examples provided, a series of modification strategies for enhancing the tumor targeting and functionality of LNPs are discussed. Thereafter, research advances on applications of these LNPs for RCC including bioimaging, liquid biopsy, drug delivery, physical therapy, and gene therapy are summarized and discussed from an interdisciplinary perspective. The final part highlights the milestone achievements of translation medicine, current challenges as well as future development directions of LNPs for the diagnosis and treatment of RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Cancer Precision Diagnosis and Treatment and Translational Medicine Hubei Engineering Research Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
- Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan, 430071, China.
ORCID-Profile: Xiongmin Mao, Zijian Wang, Hua Xu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Mao, X., Wang, G., Wang, Z., Duan, C., Wu, X., & Xu, H. (2025). Theranostic Lipid Nanoparticles for Renal Cell Carcinoma. Advanced Materials, 37(31). https://doi.org/10.1002/adma.202306246
Vancouver
Mao X, Wang G, Wang Z, Duan C, Wu X, Xu H. Theranostic Lipid Nanoparticles for Renal Cell Carcinoma. Advanced Materials. 2025;37(31). doi:10.1002/adma.202306246
BibTeX
@article{Mao2025,
author = {Mao, Xiongmin and Wang, Guanyi and Wang, Zijian and Duan, Chen and Wu, Xiaoliang and Xu, Hua},
title = {Theranostic Lipid Nanoparticles for Renal Cell Carcinoma},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {31},
doi = {10.1002/adma.202306246}
}
EUVIMED